Am J Psychiatry 158:1449-1454, September 2001
© 2001 American Psychiatric Association
Symptom Reduction and Suicide Risk Among Patients Treated With Placebo in Antipsychotic Clinical Trials: An Analysis of the Food and Drug Administration Database
Arif Khan, M.D.,
Shirin R. Khan,
Robyn M. Leventhal, B.A., and
Walter A. Brown, M.D.
OBJECTIVE: The assumption that psychotic patients assigned to placebo in clinical trials of antipsychotics are exposed to substantial morbidity and mortality is not based on data about what actually happens to such patients. This study assesses symptoms and risks of suicide and suicide attempts in psychotic patients assigned to receive placebo in clinical trials. METHOD: The authors used the Food and Drug Administration database to assess suicides, suicide attempts, and psychotic symptom reduction in clinical trials of three new antipsychotics. RESULTS: Among 10,118 participating patients, 26 committed suicide and 51 attempted suicide. Rates of suicide and attempted suicide did not differ significantly between the placebo-treated and the drug-treated groups. Annual rates of suicide and attempted suicide based on patient exposure years were 1.8% and 3.3%, respectively, with placebo; 0.9% and 5.7% with an established antipsychotic; and 0.7% and 5.0% with a new antipsychotic. Symptom reduction was 16.6% with new antipsychotics (N=1,203), 17.3% with established antipsychotics (N=261), and 1.1% with placebo (N=462). CONCLUSIONS: These data may help inform discussions about the use of placebo in antipsychotic clinical trials.
This article has been cited by other articles:
|
|
|
|
 
G. Kotzalidis, I. Pacchiarotti, G. Manfredi, V. Savoja, C. Torrent, L. Mazzarini, C. Tatarelli, B. Amann, S. Di Marzo, J. Sanchez-Moreno, et al.
Ethical questions in human clinical psychopharmacology: should the focus be on placebo administration?
J Psychopharmacol,
August 1, 2008;
22(6):
590 - 597.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. B Dunn, P. J Candilis, and L. W. Roberts
Emerging Empirical Evidence on the Ethics of Schizophrenia Research
Schizophr Bull,
January 1, 2006;
32(1):
47 - 68.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. W. Woods, R. V. Gueorguieva, C. B. Baker, and R. W. Makuch
Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia
Arch Gen Psychiatry,
September 1, 2005;
62(9):
961 - 970.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Storosum, T. Wohlfarth, C. C. Gispen-de Wied, D. H. Linszen, B. P.R. Gersons, B. J. van Zwieten, and W. van den Brink
Suicide Risk in Placebo-Controlled Trials of Treatment for Acute Manic Episode and Prevention of Manic-Depressive Episode
Am J Psychiatry,
April 1, 2005;
162(4):
799 - 802.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Healy
Shaping the Intimate:: Influences on the Experience of Everyday Nerves
Social Studies of Science,
April 1, 2004;
34(2):
219 - 245.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. W. Fleischhacker, P. Czobor, M. Hummer, G. Kemmler, R. Kohnen, and J. Volavka
Placebo or Active Control Trials of Antipsychotic Drugs?
Arch Gen Psychiatry,
May 1, 2003;
60(5):
458 - 464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Storosum, B. J. van Zwieten, T. Wohlfarth, L. de Haan, A. Khan, and W. van den Brink
Suicide Risk in Placebo vs Active Treatment in Placebo-Controlled Trials for Schizophrenia
Arch Gen Psychiatry,
April 1, 2003;
60(4):
365 - 368.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. T. Carpenter Jr., P. S. Appelbaum, and R. J. Levine
The Declaration of Helsinki and Clinical Trials: A Focus on Placebo-Controlled Trials in Schizophrenia
Am J Psychiatry,
February 1, 2003;
160(2):
356 - 362.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Y. Meltzer, L. Alphs, A. I. Green, A. C. Altamura, R. Anand, A. Bertoldi, M. Bourgeois, G. Chouinard, M. Z. Islam, J. Kane, et al.
Clozapine Treatment for Suicidality in Schizophrenia: International Suicide Prevention Trial (InterSePT)
Arch Gen Psychiatry,
January 1, 2003;
60(1):
82 - 91.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. F. Horrobin
Evidence-Based Medicine and the Need for Non-Commercial Clinical Research Directed Towards Therapeutic Innovation
Experimental Biology and Medicine,
July 1, 2002;
227(7):
435 - 437.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Does Placebo Use in Clinical Drug Trials Harm Patients with Schizophrenia?
Journal Watch Psychiatry,
October 18, 2001;
2001(1018):
7 - 7.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2001
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
